These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19407316)

  • 21. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.
    Yadegari H; Driesen J; Pavlova A; Biswas A; Hertfelder HJ; Oldenburg J
    Thromb Haemost; 2012 Oct; 108(4):662-71. PubMed ID: 22871923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinically relevant differences between assays for von Willebrand factor activity.
    Boender J; Eikenboom J; van der Bom JG; Meijer K; de Meris J; Fijnvandraat K; Cnossen MH; Laros-van Gorkom BAP; van Heerde WL; Mauser-Bunschoten EP; de Maat MPM; Leebeek FWG;
    J Thromb Haemost; 2018 Dec; 16(12):2413-2424. PubMed ID: 30358069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets.
    Cooney KA; Ginsburg D
    Blood; 1996 Mar; 87(6):2322-8. PubMed ID: 8630394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
    Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
    Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):111-8. PubMed ID: 19506357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic approach to von Willebrand disease.
    Ng C; Motto DG; Di Paola J
    Blood; 2015 Mar; 125(13):2029-37. PubMed ID: 25712990
    [No Abstract]   [Full Text] [Related]  

  • 30. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Randi AM; Shindler KS; Tuley EA; Rustagi PK; Sadler JE
    J Biol Chem; 1993 Sep; 268(27):20497-501. PubMed ID: 8376405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. von Willebrand Disease: A Concise Review and Update for the Practicing Physician.
    Swami A; Kaur V
    Clin Appl Thromb Hemost; 2017 Nov; 23(8):900-910. PubMed ID: 27920237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers.
    Ozeki M; Kunishima S; Kasahara K; Funato M; Teramoto T; Kaneko H; Fukao T; Kondo N
    Thromb Res; 2010 Feb; 125(2):e17-22. PubMed ID: 19740526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
    Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
    J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired von Willebrand Syndrome Hiding Inherited von Willebrand Disease Can Explain Severe Bleeding in Patients With Aortic Stenosis.
    Casonato A; Galletta E; Cella G; Barbon G; Daidone V
    Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2187-2194. PubMed ID: 32640909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2B or not 2B? What is the role of VWF in platelet-matrix interactions? And what is the role of the VWF:CB in VWD diagnostics? These are the questions.
    Favaloro EJ
    J Thromb Haemost; 2006 Apr; 4(4):892-4. PubMed ID: 16634760
    [No Abstract]   [Full Text] [Related]  

  • 38. Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor.
    de Jong A; Dirven RJ; Oud JA; Tio D; van Vlijmen BJM; Eikenboom J
    J Thromb Haemost; 2018 Jul; 16(7):1357-1368. PubMed ID: 29734512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developments in the diagnostic procedures for von Willebrand disease.
    De Jong A; Eikenboom J
    J Thromb Haemost; 2016 Mar; 14(3):449-60. PubMed ID: 26714181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M.
    Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
    J Thromb Haemost; 2006 Sep; 4(9):2088-90. PubMed ID: 16961623
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.